Drug discovery firm Bridge Medicines has appointed William Polvino CEO. Polvino most recently served as president and CEO of Denmark-based Veloxis Pharmaceuticals (NASDAQ: [[ticker:VELO]]), and ran Helsinn Therapeutics before that. Bridge, based in New York, launched last October to extend the work of the non-profit Tri-Institutional Therapeutics Discovery Institute. With Polvino’s appointment, Bridge says interim CEO Kathleen Metters will remain at the company in an operating role and chair its scientific advisory board.
